This 12-day study will test whether the combination of C-CSF (granulocyte-colony stimulating factor) and AMD3100 is more efficient in mobilizing stem cells for collection than the use of G-CSF alone. Traditionally, the growth factor G-CSF has been given to stem cell donors to mobilize, or push, stem cells out of the bone marrow and into the blood circulation for collection for transplantation. Although a sufficient quantity of cells usually can be collected with G-CSF treatment, some donors do not respond well and may require multiple apheresis procedures (see below) to collect enough cells. Studies indicate that G-CSF used together with a drug called AMD3100 may be more effective in mobilizing stem cells for collection than G-CSF alone. The Food and Drug Administration has approved C-CSF for stem cell mobilization. AMD3100 is a new drug that also mobilizes stem cells in large numbers within a few hours.

Normal healthy volunteers between 18 and 60 years of age may be eligible for this study. Candidates are screened with a medical history, physical examination, blood and urine tests, and electrocardiogram (EKG).

Participants undergo the following tests and procedures:

Day 1:

- Blood draw for clinical monitoring and for research studies

- Baseline abdominal ultrasound to measure spleen size

- C-CSF injection under the skin

Days 2 and 3:

- G-CSF injections under the skin

Day 4:

- G-CSF injection

- Blood draw for clinical monitoring and for research studies

- Abdominal ultrasound to monitor for changes in spleen size

- AMD3100 injection in the abdomen, arm, or thigh

Day 5:

- G-CSF injection

- Blood draw for clinical monitoring and for research studies

- Apheresis to collect stem cells. For this procedure, a catheter (plastic tube) is placed in a vein in each arm. Blood is withdrawn from one vein and circulated through a cell separator machine, which collects and saves stem cells and lymphocytes (a type of white blood cell) and returns the rest of the blood to the subject through the catheter in the vein in the other arm. The collected stem cells are not given to a patient, but are examined in the laboratory to see if they are suitable for transplant.

- Blood draw to monitor for side effects

- EKG

- Abdominal ultrasound to monitor for changes in spleen size

Days 10 through 12:

- Telephone follow-up for review of symptoms

- Blood draw to monitor for treatment side effects

Condition	Treatment or Intervention	Phase
Healthy	Drug: AMD3100	Phase II

Further Study Details: 

Expected Total Enrollment:  25

Peripheral blood progenitor cells (PBPC) are the most popular source of hematopoetic stem cells for allogeneic transplantation because of technical ease of collection and faster engraftment. Traditionally, granulocyte-colony stimulating factor (G-CSF) has been used to procure the peripheral blood stem cell graft. Although regimens using G-CSF usually succeed in collecting adequate numbers of PBPC from healthy donors, 5%-10% of the donors will mobilize stem cells poorly and may require multiple large volume apheresis or bone marrow harvesting. AMD3100 reversibly inhibits CXCR4 binding to stromal cell derived factor (SDF) - 1 and was recently discovered to be an effective agent to mobilize CD34+ cells into the peripheral blood. In normal volunteers, administering AMD3100 after 4-5 days of G-CSF resulted in a 3-3.5 fold increase in circulating CD34 cells compared to G-CSF alone. Recent data has suggested that the combination of G-CSF and AMD3100 is superior to G-CSF alone for mobilizing hematopoietic progenitor cells in heavily pretreated patients with multiple myeloma or non-hodgkin's lymphoma undergoing autologous hematopoietic transplantation. Combining AMD3100 with G-CSF could be an effective strategy to improve the yield of PBPC collected from allogeneic donors who mobilize poorly with G-CSF alone. However, the biological impact of AMD3100 in this context on T cells and other cellular populations contained within the allograft that mediate GVHD and graft-versus-leukemia (GVL) effects are unknown.

We propose to collect PBPC from healthy volunteers following 5 days of G-CSF (10 mcg/kg/day) and a single dose of AMD3100 (240 mcg/kg subcutaneous given 12 hours before starting apheresis) to study the impact of combining these two mobilizing agents on the immunological properties of the mobilized cells. A single 15 liter apheresis will be conducted on day 5 following the 5th dose of G-CSF. The immunological studies conducted on these mobilized cells will be the same as our parallel study which is investigating the immune properties of PBPCs mobilized with G-CSF or AMD3100 alone. If combining AMD3100 with G-CSF has no negative impact on the immune populations involved in GVHD and graft-vs-leukemia effects, this regimen could be used for allogeneic donors who fail to mobilize sufficient PBSC using G-CSF alone.

Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

INCLUSION CRITERIA
Healthy volunteers greater or equal to 18 years old, but less than or equal to 60 years.
Weight greater than 60 kg (132 pounds)
Normal renal function: creatinine less than 1.5 mg/dl l
Normal liver function: bilirubin less than1.5mg/dl, transaminases within normal limit
Normal blood count: WBC 3000-10000/mm3, granulocytes greater than 1500/mm3, platelets greater than 150,000/mm3, hemoglobin greater than 12.5g/dl
No history of chest pain, uncontrolled hypertension, myocardial infarction, peripheral vascular disease, transient ischemic attack, or stroke
No active infection or history of recurrent infection or positive test for syphilis (RPR), hepatitis B and C (HBsAg, Anti-HBc, Anti-HCV), HIV and HTLV-1
Subject must be eligible for normal blood donation and fit to undergo apheresis procedure (antecubital veins must be adequate for peripheral access during apheresis)
Female subjects of childbearing age must have a negative urine pregnancy test within one week of beginning G-CSF administration.
Female subjects should not be lactating.
Ability to comprehend the investigational nature of the study and provide informed consent
EXCLUSION CRITERIA: any of the following
Age less than 18 years or more than 60 years
Pregnant or lactating
Severe psychiatric illness: mental deficiency sufficiently severe as to make informed consent impossible.
History of autoimmune disease such as rheumatoid arthritis, systemic lupus erythematous
History of cancer within the past 5 years excluding basal cell or squamous cell carcinoma of the skin
History of any hematologic disorders
Diagnosis of sickle cell anemia or sickle cell trait (to be screened by Hbg electrophoresis)
History of cardiac disease or related symptoms such as tachycardia, chest pain, shortness of breath, history of cerebrovascular disease. A Framingham Coronary Disease Risk Prediction Score based on LDL cholesterol level will be calculated for each subject. Men with score above 6 and women with score above 10 will be excluded from the study
Peripheral vascular disease
Treatment with G-CSF and/or apheresis procedure within 90 days of protocol enrollment.

Maryland
      National Heart, Lung and Blood Institute (NHLBI), 9000 Rockville Pike,  Bethesda,  Maryland,  20892,  United States; Recruiting

Study ID Numbers:  040179; 04-H-0179
Record last reviewed:  April 23, 2004
Last Updated:  April 5, 2005
Record first received:  May 6, 2004
ClinicalTrials.gov Identifier:  NCT00082329
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08